C-Suite Executive | Independent Board Member | Seasoned Pharma Leader | President-Elect American Medical Women's Association | Fighting Stigma, Advancing Therapeutics, and Increasing Equity in Women’s Health

Elizabeth Garner

Chief Scientific Officer, US

Chief is a private network built to drive more women into positions of power and keep them there. Chief is the only organization specifically designed for senior women leaders to strengthen their leadership journey, cross-pollinate ideas across industries, and effect change from the top down.

Chief Member

In addition to my fulltime role as CSO, I provide short term expert consulting through my LLC.  I am qualified to provide consultation in a range of therapeutic areas, including cancer prevention and treatment, women's health, genetic testing, and surgical devices.  I also provide insights on regulatory affairs including NDA submissions and FDA Advisory Committee preparation.

Owner, President

As a member of ObsEva’s Executive Committee, I provide strategic leadership on the Company’s overall development strategy and frequently represents ObsEva to investor, Key Opinion Leader (KOL), and other key stakeholders. In my role as CMO, I lead our clinical science group, clinical operations, and pharmacovigilance.

Chief Medical Officer

As an officer of Agile Therapeutics, I played a major role in strategy development for the company, including due diliegence evaluation of business development opportunities.  As CMO I was responsible for all clinical research and development activities, including managing the clinical team, designing and leading all clinical trials and NDA submissions for Agile’s lead candidate product, the Twirla contraceptive patch, as well as development of Agile's follow-on pipeline.  I also led the Medical Affairs, pharmacovigilance and medical information functions.

Provide medical and scientific input in development of company strategy.
Serve as medical and scientific resource, representing Myriad Preventive Care to key internal and external stakeholders.
Oversee field-based Regional Medical Specialists in Preventive Care.

Vice President Medical Affairs, Preventive Care

I was a key member of the clinical development team for Elagolix (Orilissa-approved by FDA in 2018).  I designed the pivotal Phase 3 endometriosis trials and provided extensive input into the design of the Phase 2 and 3 fibroid studies, including endpoint selection, patient reported outcomes, and statistical analysis.

Senior Medical Director

Leader of Product Development Team for next generation HPV vaccine.
Clinical lead for FDA and European filings, FDA Advisory Committee Meeting.

Director

Member of Gardasil clinical team.
Protocol development, interpretation of study results, preparation of regulatory documents.

Associate Director

Assistant Professor

Surgical and medical management of complicated gynecologic cancer patients.
Research on ovarian cancer pathogenesis.
Research on HPV vaccine awareness and acceptability.